KIARA NIX: Open Payments
NPI 1245005446 · OPELIKA, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,395 in 79 payments from 10 companies in 2025. Trend: 2023 $31 · 2024 $820 · 2025 $1,395
Food & beverage: $1,395
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $275 |
| Vanda Pharmaceuticals Inc. | 13 | $244 |
| Alkermes, Inc. | 12 | $222 |
| Neurocrine BioSciences, Inc. | 10 | $222 |
| Otsuka America Pharmaceutical, Inc. | 12 | $175 |
| ABBVIE INC. | 11 | $135 |
| E.R. Squibb & Sons, L.L.C. | 3 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
Products named: CAPLYTA, FANAPT, INGREZZA, ARISTADA, VRAYLAR, ABILIFY ASIMTUFII, ABILIFY MAINTENA, REXULTI.
Industry payments across AL — which companies pay providers there.
